Academic Journal
Q3Neuroscience Applied
About Neuroscience Applied
Neuroscience Applied is a scholarly journal published by Elsevier B.V.. SCImago 2025 lists it in Q3, with an SJR of 0.764 and H-index of 10.
Coverage: 2022-2026. Research categories: Neuroscience (miscellaneous) (Q3).
Open-access policies and author information
Reported in the official DOAJ public CSV snapshot (2026-09-01), downloaded 2026-10-03. Record updated 2026-04-27. This snapshot does not establish today’s listing status or fee quotation.
Publisher policy links recorded by DOAJ
- Aims and scope ↗
- Editorial board ↗
- Instructions for authors ↗
- Peer-review policy ↗
- Publication fees ↗
- Fee waivers ↗
- Licence terms ↗
- Copyright policy ↗
- Preservation policy ↗
Source: DOAJ journal record. Journal metadata is distributed by DOAJ under CC0. Confirm current fees, tax, eligibility and waiver terms with the publisher.
Source-backed journal facts
Topics in published research
Schizophrenia research and treatment; Treatment of Major Depression; Tryptophan and brain disorders; Bipolar Disorder and Treatment; Stress Responses and Cortisol; Mental Health Research Topics.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
Variation in Public Health Reimbursement Policies of ECT and rTMS Across 28 European Countries: A Call for Evidence-Based Policy Reform from the ECNP Neuromodulation Network
Nils Opel, Jovana Bjekić, Jerome Brunelin, Jean-Marie Batail et al.
2026-09 · DOI: 10.1016/j.nsa.2026.107030Corrigendum to “Examining varying number of intervention modules and change in individual networks in young people remitted from depression or anxiety: Exploratory outcomes of the StayFine randomized clinical trial” [Neurosci. Appl. 5, (2026), 107007]
S.J. Robberegt, C.J. Albers, B.E.A.M. Kooiman, A.H. Vuuregge et al.
2026-09 · DOI: 10.1016/j.nsa.2026.107025Progress and novel insights in neuropsychiatric research using induced pluripotent stem cell (iPSC)-Derived models
Edna Grünblatt
2026-05 · DOI: 10.1016/j.nsa.2026.107010Driving innovation of clinical trials outcomes in neuroscience
Silvia Zaragoza Domingo
2026-03 · DOI: 10.1016/j.nsa.2026.106997Corrigendum to “Cognitive phenotypes within and across major depression and schizophrenia: data-driven exploratory transdiagnostic and intra-diagnostic latent profile analyses” [Neurosci. Appl., Volume 5 (2026) 106040]
Benjamin J.M. Gooddy, Laila Rida, Bryony Goulding-Mew, Luisa Schalk et al.
2026-02 · DOI: 10.1016/j.nsa.2026.106983Fairness without flexibility: impaired social decision-making in harmful alcohol use
M. Chueca Arteaga, T.V. Lim, K.D. Ersche
2026 · DOI: 10.1016/j.nsa.2025.106445Massively parallel characterization of common genetic risk variants for mental health disorders in glutamatergic neurons
L. Fischer, N.F. Page, Z. Chen, A. Kundaje et al.
2026 · DOI: 10.1016/j.nsa.2025.106580Beyond mood: a systematic review and network meta-analysis of the physiological and cardiometabolic effects of antidepressants
A. Arumuham, T. Pillinger, R. McCutcheon, E. D'Ambrosio et al.
2026 · DOI: 10.1016/j.nsa.2025.106359Global increases in brain glucose metabolism following acute N,N-dimethyltryptamine and harmine administration in healthy volunteers: An [18F]FDG-PET study
K. Egger, R. Bozsak, H.D. Aicher, H. Sari et al.
2026 · DOI: 10.1016/j.nsa.2025.106388Social support during mid-pregnancy and fetal brain-derived neurotrophic factor at birth
E.K. Lamadé, R. Hellweg, M. Deuschle
2026 · DOI: 10.1016/j.nsa.2025.106348Effect of depression-related NAD+/SIRT1 pathway polygenic risk score on functional connectivity of the nucleus accumbens
D. Török, S. Krause, K. Gecse, Z. Gal et al.
2026 · DOI: 10.1016/j.nsa.2025.106148Exploring the therapeutic potential of medical cannabis use in individuals with autism spectrum disorder: systematic review
C. Fe, L. Shafira Lopes de Souza Oliveira, M. Coutinho de Oliveira Filho, R.A.D.M.E.A. França et al.
2026 · DOI: 10.1016/j.nsa.2025.106202Affective temperaments and their role in medication adherence and infertility treatment outcomes: preliminary insights from a prospective longitudinal follow-up study
K. Soltesz, G. Szabo, J. Szigeti, M. Sipos et al.
2026 · DOI: 10.1016/j.nsa.2025.105738Wish to live, wish to die, and suicidal ambivalence: associations with clinical factors and suicide risk assessment in psychiatric inpatients
E. Palocz, A. Miklosi, L.P. Elek, S. Kacimi El Hassani et al.
2026 · DOI: 10.1016/j.nsa.2025.105658A role for prefrontal dopamine signaling in behavioral flexibility
A. Petitbon, A. Contini, R. Walle, M.C. Allichon et al.
2026 · DOI: 10.1016/j.nsa.2026.106902Educational attainment and white matter microstructure in psychiatric disorders:: a diffusion-imaging study
J.M. Hubbert, L.M. Bonnekoh, J. Krieger, C. Jurischka et al.
2026 · DOI: 10.1016/j.nsa.2026.106910Self-reported benefits and harms of microdosing with natural psilocybin: preliminary results from a naturalistic study
I. Totomanova, E.C.H.M. Haijen, P.P.M. Hurks, N.L. Mason et al.
2026 · DOI: 10.1016/j.nsa.2026.106942Contribution of neural circuits of the insular cortex in obesity-induced anxiety
P. Léa, E. Ducourneau, L. Rouzoul, V. Gomez et al.
2026 · DOI: 10.1016/j.nsa.2026.106977The role of patient-reported outcome measures in schizophrenia and bipolar disorder: a network analysis study
S.F. Aprile, A. Rodolico, S. Castellano, P. Cutrufelli et al.
2026 · DOI: 10.1016/j.nsa.2026.106955Optimising trazodone use in major depressive disorder: results from a European delphi panel
A. Young, A. Fagiolini, L. Agüera-Ortiz, M. Siwek et al.
2026 · DOI: 10.1016/j.nsa.2025.106483Reviews
Community Reviews
Version History
October 2, 2026 at 9:01 pm
October 2, 2026